Human interleukin-2
- Generic Name
- Human interleukin-2
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- FNO32LO217
- Background
Human interleukin-2 is under investigation in clinical trial NCT03475134 (TIL-ACT After NMA Chemo With IL-2 and Nivo Rescue in mMEL).
- Associated Conditions
- -
- Associated Therapies
- -
Novel Interventions in HIV-1 Infection
- Conditions
- Interventions
- First Posted Date
- 2010-05-26
- Last Posted Date
- 2013-09-04
- Lead Sponsor
- Imperial College London
- Target Recruit Count
- 12
- Registration Number
- NCT01130376
- Locations
- 🇬🇧
St. Stephen's AIDS Trust, London, United Kingdom
High Dose Interleukin-2 Followed by Intermittent Low Dose Temozolomide in Patients With Melanoma
- First Posted Date
- 2010-05-17
- Last Posted Date
- 2019-02-12
- Lead Sponsor
- Milton S. Hershey Medical Center
- Target Recruit Count
- 17
- Registration Number
- NCT01124734
- Locations
- 🇺🇸
Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States
Haploidentical Natural Killer Cells to Treat Refractory or Relapsed Acute Myelogenous Leukemia (AML)
- First Posted Date
- 2010-04-20
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 15
- Registration Number
- NCT01106950
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer
- First Posted Date
- 2010-04-16
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 13
- Registration Number
- NCT01105650
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies
- First Posted Date
- 2009-08-31
- Last Posted Date
- 2023-12-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 34
- Registration Number
- NCT00968760
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Immune Mobilization of Autologous Peripheral Blood Stem Cells Using Interleukin-2 and GM-CSF
- Conditions
- Interventions
- First Posted Date
- 2009-08-06
- Last Posted Date
- 2018-04-25
- Lead Sponsor
- Dartmouth-Hitchcock Medical Center
- Target Recruit Count
- 13
- Registration Number
- NCT00952237
- Locations
- 🇺🇸
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
Haploidentical Natural Killer (NK) Cells With Epratuzumab for Relapsed Acute Lymphoblastic Leukemia (ALL)
- Conditions
- Interventions
- First Posted Date
- 2009-07-20
- Last Posted Date
- 2014-05-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 2
- Registration Number
- NCT00941928
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Interleukin-2 Treatment for Wiskott-Aldrich Syndrome
- Conditions
- Interventions
- First Posted Date
- 2008-10-17
- Last Posted Date
- 2017-08-16
- Lead Sponsor
- Soma Jyonouchi
- Target Recruit Count
- 9
- Registration Number
- NCT00774358
- Locations
- 🇺🇸
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸The Texas Children's Hospital, Houston, Texas, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Haploidentical Natural Killer (NK) Cells in Patients With Relapsed or Refractory Neuroblastoma
- Conditions
- Interventions
- First Posted Date
- 2008-06-16
- Last Posted Date
- 2020-09-24
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 1
- Registration Number
- NCT00698009
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Study Comparing Association Between Sorafenib and Interleukin-2 (IL-2) Versus Sorafenib in 1st Line Therapy in Advanced (Adv) Renal Cell Carcinoma (RCC)
- Conditions
- Interventions
- First Posted Date
- 2008-02-07
- Last Posted Date
- 2009-02-26
- Lead Sponsor
- Italian Trial in Medical Oncology
- Target Recruit Count
- 90
- Registration Number
- NCT00609401
- Locations
- 🇮🇹
Istituto Tumori, Milano, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.